Kymera Therapeutics, Inc.
KYMR
$82.21
-$2.29-2.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.37M | 2.87M | 2.76M | 11.48M | 22.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.37M | 2.87M | 2.76M | 11.48M | 22.10M |
| Cost of Revenue | 98.16M | 83.83M | 74.09M | 78.39M | 80.26M |
| Gross Profit | -63.80M | -80.96M | -71.33M | -66.91M | -58.16M |
| SG&A Expenses | 20.36M | 16.94M | 17.34M | 17.65M | 16.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 118.52M | 100.77M | 91.43M | 96.03M | 96.53M |
| Operating Income | -84.15M | -97.90M | -88.67M | -84.56M | -74.43M |
| Income Before Tax | -69.23M | -86.98M | -82.18M | -76.61M | -65.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.23M | -86.98M | -82.18M | -76.61M | -65.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.23M | -86.98M | -82.18M | -76.61M | -65.58M |
| EBIT | -84.15M | -97.90M | -88.67M | -84.56M | -74.43M |
| EBITDA | -82.13M | -97.46M | -85.82M | -83.17M | -72.38M |
| EPS Basic | -0.71 | -0.97 | -0.94 | -0.95 | -0.82 |
| Normalized Basic EPS | -0.44 | -0.60 | -0.56 | -0.60 | -0.51 |
| EPS Diluted | -0.71 | -0.97 | -0.94 | -0.95 | -0.82 |
| Normalized Diluted EPS | -0.44 | -0.60 | -0.56 | -0.60 | -0.51 |
| Average Basic Shares Outstanding | 97.53M | 89.91M | 87.30M | 80.45M | 80.15M |
| Average Diluted Shares Outstanding | 97.53M | 89.91M | 87.30M | 80.45M | 80.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |